Byondis B.V.: Preclinical Data on the Potential of Byondis ADC BYON3521 Published in Molecular Cancer Therapeutics

Overexpressed in Solid TumorsADC Currently in a First-in-Human Study NIJMEGEN, Netherlands, April 12, 2023 /PRNewswire/ -- Byondis B.V., an independent, clinical-stage Dutch biopharmaceutical

Related Keywords

Netherlands ,United Kingdom ,Italy ,Nijmegen ,Gelderland ,Belgium ,United States ,Dutch ,American ,Prnewswire Byondis ,Wim Dokter ,Conjugation Technology ,First In Human Study ,Molecular Cancer Therapeutics ,American Association ,Cancer Research ,Byondis Chief Scientific Officer Wim Dokter ,Next Generation Antibody Drug ,Proprietary Linker Drug ,Site Specific Conjugation ,Good Manufacturing Practice ,Byondis ,Reclinical ,Data ,Potential ,Yon3521 ,Published ,Olecular ,Dancer ,Herapeutics ,